Expertise in
4
conditions

Jean-marc M. Ferrero

33 Avenue De Valombrose, 
Nice, FR 
Expertise in
4
conditions
33 Avenue De Valombrose, 
Nice, FR 
OverviewLocationsClinical Research

Overview

Jean-marc Ferrero practices in Nice, France. Ferrero is highly rated in 4 conditions, according to our data. Their top areas of expertise are Breast Cancer, Breast Cancer in Men, Triple-Negative Breast Cancer, Febrile Neutropenia, and Mastectomy.

Their clinical research consists of co-authoring 143 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

33 Avenue De Valombrose, Nice, 06189, France
Other Locations
Sophia Antipolis, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.
A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.
Enrollment Status: Active_not_recruiting
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab Injection, Neoadjuvant EC-Paclitaxel Chemotherapy
Study Phase: Phase 2
Adjuvant Systemic Treatment for Oestrogen-receptor (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment. A French UNICANCER Geriatric Oncology Group (GERICO) and Breast Group (UCBG) Multicentre Phase III Trial
Adjuvant Systemic Treatment for Oestrogen-receptor (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment. A French UNICANCER Geriatric Oncology Group (GERICO) and Breast Group (UCBG) Multicentre Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 26, 2025
Intervention Type: Drug
Study Drugs: Hormonotherapy, Chemotherapy then Hormonotherapy
Study Phase: Phase 3
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Drug
Study Drugs: AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, Vandetanib, Bicalutamide, Olaparib, Anthracyclines, Taxanes, Cyclophosphamide, DNA Intercalators, Methotrexate, Vinca Alkaloids, Platinum Based Chemotherapies, Bevacizumab, Mitomycin C, Eribulin, MEDI4736
Study Phase: Phase 2
A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer
A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer
Enrollment Status: Terminated
Publish Date: November 28, 2022
Intervention Type: Drug
Study Drugs: Alpelisib, Chemotherapy
Study Phase: Phase 2
Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women
Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women
Enrollment Status: Completed
Publish Date: September 21, 2022
Intervention Type: Procedure
Study Phase: Not Applicable
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
Enrollment Status: Completed
Publish Date: September 16, 2022
Intervention Type: Drug
Study Phase: Phase 2
Pharmacogenetic Study in Castration-resistant Prostate Cancer Patients Treated With Abiraterone Acetate
Pharmacogenetic Study in Castration-resistant Prostate Cancer Patients Treated With Abiraterone Acetate
Enrollment Status: Completed
Publish Date: December 04, 2020
Intervention Type: Drug
Study Phase: Not Applicable
Impact of a Telephonic Monitoring During Neo Adjuvant or Adjuvant Chemotherapy
Impact of a Telephonic Monitoring During Neo Adjuvant or Adjuvant Chemotherapy
Enrollment Status: Completed
Publish Date: July 23, 2019
Intervention Type: Other
Study Phase: Not Applicable
Role of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Patients Wih Leptomeningeal Metastasis of Breast Cancer. A Randomized Phase III Study.
Role of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Patients Wih Leptomeningeal Metastasis of Breast Cancer. A Randomized Phase III Study.
Enrollment Status: Completed
Publish Date: June 12, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

143 Total Publications

PROTACs and Glues: Striking Perspectives for Engineering Cancer Therapy À La Carte.
PROTACs and Glues: Striking Perspectives for Engineering Cancer Therapy À La Carte.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: July 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ferrero's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile